linjc16/ctgov huggingface dataset:
The Addition of Self-compassion Skills Training to a Behavioral Weight Loss Program Delivered Using Video Conferencing Software

Study Overview
=================
Brief Summary
-----------------
The current study examined the efficacy, feasibility, and acceptability of: 1) adding self-compassion (SC) skills training to a standard behavioral weight loss program (BWLP), and 2) utilizing video conferencing software to deliver small group, weekly, weight loss classes.

Detailed Description
-----------------
Object: The current study examined the efficacy, feasibility, and acceptability of: 1) adding self-compassion (SC) skills training to a standard behavioral weight loss program (BWLP), and 2) utilizing video conferencing software to deliver small group, weekly, weight loss classes. Method: The BWLP program utilized Webex video conferencing software to deliver a 12-week, interactive, small group, weekly weight loss intervention. Participants were randomized to a standard BWLP or a standard behavioral weight loss program augmented with self-compassion skills training (BWLP+SC).

Official Title
-----------------
The Addition of Self-compassion Skills Training to a Behavioral Weight Loss Program Delivered Using Video Conferencing Software

Conditions
-----------------
Weight Loss

Intervention / Treatment
-----------------
* Behavioral: Behavioral weight loss program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 or older, at a BMI of 27 kg/m2 or greater, and available to attend weekly online groups Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Standard weight loss<br>A 12 week small group weight loss intervention delivered via video teleconference technology. | Behavioral: Behavioral weight loss program<br>* A 12 week small group weight loss program delivered via teleconference video technology<br>|
| Experimental: Standard weight loss plus self-compassion skills training<br>A 12 week small group weight loss intervention delivered via video teleconference technology. | Behavioral: Behavioral weight loss program<br>* A 12 week small group weight loss program delivered via teleconference video technology<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weight loss | Weight in kilograms | 12 weeks | 
| height | meters | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-compassion | Change in self-compassion scale score from pre to post | 12 weeks | 
| Eating Behaviors | Change in eating behaviors scale from pre to post | 12 weeks |
Study of Rotatory Vestibular Tests in Major Depression Patients and Healthy Control Subjects.

Study Overview
=================
Brief Summary
-----------------
This study evaluates the vestibular activity in major depression patients and healthy controls using the rotatory test and electronystagmography.

Detailed Description
-----------------
Previous studies showed abnormal vestibular activity in major depression patients using caloric vestibular tests. The present study investigates the vestibular response to vestibular rotatory tests in major depression subjects and healthy controls.

Official Title
-----------------
Study of Rotatory Vestibular Tests in Major Depression Patients and Healthy Control Subjects.

Conditions
-----------------
Depression, Vestibular Disorder

Intervention / Treatment
-----------------
* Diagnostic Test: Rotatory vestibular test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male and females adults (18 years or older) met the Diagnosing and Statistical Manual of Mental Disorders (DSM-IV-R, American Psychiatric Association, 2000) criterion. had a score of 12 or more in the Hamilton Rating Scale, 21 items for Depression. with or without actual pharmacological treatment, except benzodiazepines that were suspended 24 hours before the rotary test when corresponding. Exclusion Criteria: pregnant women neurologic disorders.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Major Depression Group<br>We will measure the vestibular activity of Major depression patients with Rotatory Test and electronystagmography | Diagnostic Test: Rotatory vestibular test<br>* We will measure Depression and Healthy subjects vestibular activity by Rotatory Vestibular tests<br>|
| Healthy Control Group<br>We will measure the vestibular activity of Healthy subjects with Rotatory Test and electronystagmography. | Diagnostic Test: Rotatory vestibular test<br>* We will measure Depression and Healthy subjects vestibular activity by Rotatory Vestibular tests<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vestibular Activity | The primary outcome corresponds to the vestibular activity. The vestibular stimulation provided by the rotatory chair is sensed by the inner ear´s vestibular receptors and generates reflex ocular movements(Vestibulo Ocular Reflex) registrated by electronystagmography. The main outcome corresponds to the asymmetry of the vestibular activity between both ears. | Vestibular rotatory test for each participant is about 50- 60 minutes. One rotatory test per participant. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
depression, vestibular disorder, rotatory test, electronystagmography
The Effect of Tai Chi in Treating Fibromyalgia

Study Overview
=================
Brief Summary
-----------------
To evaluate the effect of Tai chi on Fibromyalgia

Conditions
-----------------
Fibromyalgia

Intervention / Treatment
-----------------
* Other: Taichi
* Other: Dance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 40 years of age or older meeting the classification of FM per the 1990 ACR criteria approval by a healthcare provider for participation Exclusion Criteria: had practiced Tai chi within the past 6 months had exercised >30 min three times weekly for past 3 months could not independently ambulate without assistive devices had BPI pain severity or interference scores less than 5 had planned elective surgery during study period were actively involved in health-related litigation were unwilling to keep all treatments/medications steady throughout the study period

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Taichi<br>patients exercise with Tai chi | Other: Taichi<br> <br> |
| Sham Comparator: Control<br>patients under exercise of dance | Other: Dance<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fibromyalgia Impact Questionnaire (FIQ) |  | up to 48 weeks |
Intrapartum Maternal Oxygen Supplementation: Effects on the Mother and Neonate

Study Overview
=================
Brief Summary
-----------------
Approximately 2/3 of laboring women receive supplemental oxygen (O2) in an attempt to reverse perceived fetal hypoxia on electronic fetal monitoring (EFM). O2 supplementation is most commonly used in patients with Category II EFM, a class of EFM patterns designed in part to identify fetal acidemia. This liberal use of O2 in laboring patients is concerning because hyperoxygenation in infants is associated with adverse outcomes including retinopathy and abnormal neurodevelopment. Furthermore, excess O2 exposure is linked to free radical generation and subsequent oxidative cell damage. This calls for a closer look at the safety of intrauterine O2 exposure. The proposed project explores potential mechanisms for harm with maternal O2 supplementation in laboring patients with Category II EFM. Specifically, this project will determine the effect of O2, compared to room air (RA), on umbilical cord and maternal levels of malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), markers of free radical-induced oxidative stress. The study will also explore the correlation between urinary and blood markers of oxidative stress. Banked specimens will be used to investigate the potential effect of peripartum O2 exposure on placental oxidative stress in the future.

Official Title
-----------------
Intrapartum Maternal Oxygen Supplementation: Effects on the Mother and Neonate

Conditions
-----------------
Intrauterine Resuscitation

Intervention / Treatment
-----------------
* Other: No oxygen
* Other: Oxygen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Singleton Gestational age ≥37 weeks Spontaneous labor or induction of labor English speaking Ability to give informed consent Exclusion Criteria: Major fetal anomaly Multiple gestation Category III electronic fetal monitoring Maternal hypoxia Preeclampsia Intrauterine growth restriction Pregestational diabetes Tobacco use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Room air<br>Room air (no mask) | Other: No oxygen<br>* No facemask, room air only<br>* Other names: Room air;|
| Placebo Comparator: Oxygen<br>10L/min Oxygen by facemask | Other: Oxygen<br>* 10Liters/minute oxygen by facemask<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Umbilical artery malondialdehyde |  | At delivery | 
| Umbilical artery 4-hydroxynonenal |  | At delivery | 
| Maternal malondialdehyde |  | Within 1 hour of delivery | 
| Maternal 4-hydroxynonenal |  | Within 1 hour of delivery |
The Model Building and Empirical Research of Eye Health Interventions for Children

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Eye Health Intervention can obviously reduce and delay myopia onset and development and improved the awareness rate of knowledge apparently .

Official Title
-----------------
Vice-president, Nurse, Principal Investigator

Conditions
-----------------
Myopia

Intervention / Treatment
-----------------
* Behavioral: eye health education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: primary 1-3 grade students Exclusion Criteria: ocular inflammation eye injury dysgnosia

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: eye health education<br> | Behavioral: eye health education<br>* give a lecture and issue knowledge manual for children and parents ,6 months once , 2.5 years<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Myopia |  | every 6 months, total 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| health of eyes knowledge |  | every 6 months, total 3 years, questionnair | 
| health of eyes behavior |  | every 6 months, total 3 years, questionnaire | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
myopia
The Effects of Two Different Orthosis on Pain, Hand Strength and Function in Patients With Thumb Carpometacarpal Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
The investigators aimed to assess the effects of two different hand orthosis on hand functioning, pain, disability and quality of life in patients with thumb osteoarthritis

Detailed Description
-----------------
The investigators will randomized 60 patients with stage 1 or 2 thumb osteoarthritis in two groups. The investigators will prescribe a neoprene CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2. The investigators will recommend these orthosis for six weeks. They will assess pain and disability before and after the treatment.

Official Title
-----------------
The Effects of Hand Orthosis in Thumb Osteoarthritis

Conditions
-----------------
Osteoarthritis Thumb

Intervention / Treatment
-----------------
* Other: orthosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being aged between 18 and 70 Grade 1 or 2 thumb osteoarthritis Exclusion Criteria: The other hand disorders such as fracture and carpal tunnel syndrome Previous hand surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized controlled prospective trial
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: neoprene CMC orthosis<br>We will prescribe a neopren CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2 | Other: orthosis<br>* Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis<br>|
| Experimental: thermoplastic CMC orthosis<br>We will prescribe a neoprene CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2 | Other: orthosis<br>* Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUSCAN (Australian Canadian Oateoarthritis Hand Index) | This scale is used to assess of pain, disability and stiffness. Change is being assesed. Total score is ranged between 0-90. | before the treatment, end of the sixth week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
osteoarthritis thumb, orthosis, functioning
Testing the Effects of an Algorithm for Neuropathic Pain on Patient and System Outcomes

Study Overview
=================
Brief Summary
-----------------
The overall purpose of this project is to improve nurse skills regarding neuropathic pain (NP) assessment, treatment and referral practices through implementation of an evidence-based algorithm and to improve selected patient outcomes as a result of algorithm use.

Detailed Description
-----------------
Neuropathic pain (NP) is defined as pain that arises from injury, disease or dysfunction of the central or peripheral nervous system. For the patient focused phase of the project NP treatment will be guided via the Peripheral Neuropathy Treatment Algorithm. Patients will receive algorithm-specific treatment for 12 weeks.

Official Title
-----------------
Testing the Effects of an Algorithm for Neuropathic Pain on Patient and System Outcomes

Conditions
-----------------
Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cancer patients experiencing NP from a variety of causes NP Visual Analogue Scale (VAS) score equal to or > 4 with 12 week estimated duration Karnofsky Performance Status (KPS) 60% or greater Age greater than 18 Exclusion Criteria: Patients undergoing anticancer or invasive pain procedures specifically intended to palliate NP are ineligible

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To implement an evidence based screening, assessment, treatment, and referral guideline for hematology/oncology patients with NP receiving care |  | outcome measures will consist of the NPVAS, and a PPCPS adapted rom the original project. Adequate satisfaction will be defined as 25% or mor of all patients reporting being very or completely satisfied as measured by PPCPS |
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can be obtained at a neutral cost as compared to SA mono therapy. Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and intramyocellular fat.

Official Title
-----------------
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients: Impact on Insulin Sensitivity, Glucose Tolerance, and Pharmacoeconomics

Conditions
-----------------
Acromegaly, Insulin Resistance, Impaired Glucose Tolerance

Intervention / Treatment
-----------------
* Drug: Pegvisomant
* Drug: Somatostatin analog (lanreotide or octreotide)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 Diagnosed with acromegaly Safe anticonceptive for fertile women Well controlled on somatostatin analog (a serum IGF-I within normal range a nadir GH < 0.5 µg/l.) Exclusion Criteria: Pregnancy Liver disease Diabetes mellitus type I Magnetic or electronic implants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Co-treatment with Pegvisomant (15-30 mg twice a week) and a 50 percent reduced somatostatin-analog dose | Drug: Pegvisomant<br>* Pegvisomant s.c 15-30 mg 2 times a week<br>* Other names: Somavert;Drug: Somatostatin analog (lanreotide or octreotide)<br>* Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog<br>|
| Active Comparator: 2<br>Somatostatin analog, unaltered dosage | Drug: Somatostatin analog (lanreotide or octreotide)<br>* Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin sensitivity |  | 0 and after 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose tolerance |  | 0 and after 24 weeks | 
| Symptoms, QoL questionaire |  | 0, 12 and 24 weeks | 
| Intrahepatic and intramyocellular fat |  | 0 and 24 weeks | 
| Substrate metabolism |  | 0 and 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acromegaly, Insulin sensitivity, Glucose tolerance, Body composition, Growth Hormone
The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment

Study Overview
=================
Brief Summary
-----------------
The efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment

Detailed Description
-----------------
We compare the effect of risedronate with placebo in bone mineral density changes in patients receiving high dose corticosteroids for their underlying diseases

Conditions
-----------------
Osteoporosis

Intervention / Treatment
-----------------
* Drug: risedronate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with various medical conditions who require high dose glucocorticoid treatment: (1) pulse methylprednisolone; (2) oral prednisolone (>=0.8mg/kg/day) or equivalent for at least 6 weeks. Age>=18 years and <75 years. Exclusion Criteria: Pregnant or lactating women. Uncorrected hypocalcemia. History of esophageal stricture. Previous intolerance or hypersenstivity to biphosphonates.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: risedronate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bone mineral density |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events, new vertebral fractures |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
corticosteroids, bone mineral, risedronate, bisphosphonate